AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
CRISM Therapeutics Corporation (AIM: CRTX), a UK-based clinical-stage company focused on targeted and sustained chemotherapy delivery, has published findings from an independent third-party shareholder register analysis as of 30 June 2026. The report highlights eight major shareholders each holding 3% or more of the company's ordinary shares, with Miton UK Smaller Companies Fund leading at 9.47%. This disclosure offers investors enhanced transparency into CRISM's shareholder structure during a pivotal phase in advancing its ChemoSeed cancer treatment technology.
Key Highlights
- CRISM Therapeutics Corporation (AIM: CRTX) specialises in drug delivery technology for localized chemotherapy targeting solid tumors and glioblastoma.
- An independent third-party analysis of the shareholder register as of 30 June 2026 identified eight shareholders each owning at least 3% of ordinary shares.
- Miton UK Smaller Companies Fund holds the largest stake with 7,500,000 shares (9.47%), followed by Executive Chairman Andrew Webb at 9.22%.
- The combined holdings of these eight significant shareholders represent approximately 56.83% of CRISM's ordinary share capital.
- This disclosure aligns with standard regulatory practices for AIM-listed firms, enhancing investor understanding of share ownership.
Miton UK Smaller Companies Fund Secures Largest Stake in CRISM Therapeutics
Miton UK Smaller Companies Fund has become the largest disclosed shareholder in CRISM Therapeutics, holding 7,500,000 ordinary shares, equivalent to 9.47% of the company's share capital as of 30 June 2026. This substantial investment underscores institutional confidence in CRISM's innovative drug delivery platform and signals recognition of the company's potential within the smaller-cap UK equity sector. The fund's involvement lends professional validation and may support CRISM's future capital raising and shareholder stability during its clinical development phase.
The prominence of Miton UK Smaller Companies Fund is notable given CRISM's clinical-stage status, with its lead product ChemoSeed still undergoing development without current revenue generation. This investment pattern reflects institutional backing focused on long-term growth prospects rather than immediate returns.
Executive Chairman Andrew Webb and CSO Dr Christopher McConville Hold Significant Personal Stakes
Andrew Webb, Executive Chairman, owns 7,297,190 ordinary shares (9.22%), making him the second-largest shareholder. His considerable personal investment aligns his interests closely with those of shareholders and signals strong confidence in CRISM's strategic direction and drug delivery technology.
Chief Scientific Officer Dr Christopher McConville holds 4,992,033 shares (6.30%), highlighting the scientific leadership's commitment to CRISM's platform and clinical programs. Together, Webb and McConville control approximately 15.52% of the company's ordinary shares, reflecting robust insider ownership typically viewed favorably by investors.
Additional Major Shareholders Include Brian Murray and David Lawton
Besides the fund and company executives, six other shareholders each hold 3% or more of CRISM's ordinary shares. Brian Murray owns 4,908,700 shares (6.20%), and David Lawton holds 4,012,220 shares (5.07%). This indicates a shareholder base with significant capital commitments and a relatively distributed ownership structure common among clinical-stage firms with multiple funding rounds.
Other notable shareholders include Zeus Dynamic Opportunities Fund with 3,150,000 shares (3.98%), Hobart Capital Markets LLP holding 2,830,000 shares (3.57%), and John Rylands with 2,388,892 shares (3.02%). The mix of specialist funds, individual investors, and market participants demonstrates a diverse investor base supporting CRISM's development. Collectively, these eight shareholders hold about 56.83% of the ordinary share capital.
ChemoSeed Platform Addresses Critical Needs in Solid Tumor and Glioblastoma Treatment
CRISM Therapeutics has developed ChemoSeed, a pioneering drug delivery system designed to enhance cancer treatment by enabling localized, sustained chemotherapy delivery directly to tumor sites. Implantable in tumors or at surgical resection margins, ChemoSeed aims to deliver therapeutic drug levels deep into tumor tissue, potentially improving efficacy over systemic chemotherapy while reducing systemic toxicity.
The technology holds particular promise for glioblastoma, an aggressive brain tumor with limited treatment options due to the blood-brain barrier restricting chemotherapy access. ChemoSeed's direct implantation during surgery bypasses this barrier, potentially offering meaningful clinical benefits for patients with significant unmet medical needs. The platform leverages existing chemotherapy drugs by delivering them innovatively rather than developing new compounds.
AIM Listing and Independent Shareholder Analysis Demonstrate Regulatory Compliance and Transparency
As an AIM-listed company on the London Stock Exchange, CRISM Therapeutics adheres to regulatory requirements for disclosure of substantial shareholdings and accurate share registers. The independent third-party shareholder register analysis as of 30 June 2026 exemplifies CRISM's commitment to transparency and regulatory compliance, providing investors and regulators with verified information on significant shareholders.
The 3% disclosure threshold aligns with UK listing rules and takeover code standards, identifying holdings material enough to influence corporate governance or trigger regulatory actions. Such transparency supports investor protection and governance by revealing potential conflicts, control changes, or shareholder activism risks. This analysis and disclosure reinforce CRISM's adherence to best practices, crucial for maintaining investor confidence during clinical development.
Clinical-Stage Status and Shareholder Diversity Reflect Capital Needs and Growth Path
CRISM remains a clinical-stage biotech company, with ChemoSeed yet to receive regulatory approval or commercialization. The capital-intensive nature of clinical development necessitates funding for research, trials, regulatory processes, and manufacturing scale-up. The disclosed shareholder mix—including institutional investors, founders, executives, and financial stakeholders—reflects typical investor diversity for companies at this stage.
The timing of this shareholder analysis coincides with ongoing clinical advancement of ChemoSeed, though specific trial phases or timelines were not disclosed. Investors understand the inherent risks and extended timelines in biotech development. The presence of both long-term institutional investors and insiders with significant stakes suggests confidence in CRISM's technology and prospects. Future capital raises are likely to support continued development, with the current shareholder base providing a foundation for funding access.
Strong Insider Ownership Aligns Management and Shareholder Interests
The combined 15.52% ownership by Executive Chairman Andrew Webb and Chief Scientific Officer Dr Christopher McConville aligns leadership incentives with shareholder value creation. Such significant insider holdings are generally viewed positively, as they tie management’s financial outcomes directly to company performance, reducing conflicts between executives and investors.
Dr McConville’s role as CSO underscores the importance of scientific leadership in CRISM’s drug delivery focus. His substantial stake reflects commitment to the scientific vision and clinical strategy underpinning ChemoSeed. This insider involvement is a key value driver in clinical-stage biotech, where scientific and clinical success are critical. The market may interpret these holdings as indicators of management confidence, especially during clinical or regulatory milestones.
Independent Third-Party Analysis Ensures Accurate Shareholder Disclosure
The shareholder register analysis was performed by an independent third party, enhancing the credibility and accuracy of disclosed significant shareholders. This external verification involved detailed review of share registers and regulatory data, ensuring reliable identification of major holdings. Independent analysis is a corporate governance best practice, providing assurance to investors and regulators.
The analysis date of 30 June 2026 offers a precise snapshot of share ownership, though registers are dynamic and holdings may have changed since. The announcement includes contact details for inquiries, with financial PR support from Burson Buchanan and Nomad, and broker services from S.P. Angel Corporate Finance LLP, both established AIM market advisors overseeing compliance and disclosure.
Investment Context: Clinical-Stage Biotech Risks and Institutional Support
Operating in the high-risk, high-reward clinical-stage biotech sector, CRISM Therapeutics attracts sophisticated investors aware of development uncertainties. Institutional funds like Miton UK Smaller Companies Fund and Zeus Dynamic Opportunities Fund have evaluated CRISM’s technology and market potential, allocating capital accordingly. Their participation validates CRISM’s investment proposition within the smaller-cap equity space.
The shareholder composition balances founder and insider capital with institutional and specialist investors, a healthy mix supporting governance and funding needs. This foundation positions CRISM for potential future capital raises essential for advancing ChemoSeed through clinical trials, regulatory approval, and commercialization.
This article is for informational purposes only and does not constitute investment advice. The information is based solely on CRISM Therapeutics Corporation's announcement and does not represent an offer to buy or sell securities. Clinical-stage biotech investments carry significant risks, including potential development failure, regulatory denial, or commercial challenges. Prospective investors should perform independent due diligence, review regulatory filings, and seek professional advice before investing. Past performance and public disclosures do not guarantee future results. Shareholder information reflects positions as of 30 June 2026 and may have changed subsequently.
